Overview
The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease.
Full Product Details
Author: Tamas Bartfai (PhD, The Scripps Research Institute, La Jolla, CA<br>Harold L. Dorris Neurological Research Center and Scripps Research Institute, La Jolla, California, USA) ,
Graham V. Lees (PhD, Publishing Consultant, Corpus Alienum Oy, Finland)
Publisher: Elsevier Science Publishing Co Inc
Imprint: Academic Press Inc
Dimensions:
Width: 15.20cm
, Height: 2.30cm
, Length: 22.90cm
Weight: 0.600kg
ISBN: 9780124071803
ISBN 10: 0124071805
Pages: 376
Publication Date: 03 July 2013
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Paperback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Reviews
A remarkable compendium of hard data and wise prescription for the pharmaceutical industry. - Michael S. Brown, 1985 Novel Laureate in Medicine or Physiology, UT Southwestern Medical Center This is an extraordinary, insightful and provocative book that should be read by all those concerned by the progress of biomedicine, from scientists to politicians. - Jean-Pierre Changeux, College de France and l'Institut Pasteur Bartfai and Lees raise critical issues confronting the search for new medicines. Their analysis is cogent, and their proposals thoughtful and thought provoking. For anyone curious about where new medicines come from, and what it will take for the BioPharma industry to bring new treatments to patients with Alzheimer's disease, diabetes, depression, cancer, and more, this is a must read. - Michael D. Ehlers, Senior VP Pfizer and CSO Neuroscience, former Howard Hughes Investigator, Duke University This book is a must read for students, prescribing physicians, academic and industry researchers, analysts, patient groups, business and science journalists, and importantly, Policy Makers. More than ever before, drug development is a complex scientific, industrial and societal endeavour that needs the combined attention of Governments, Academics and Big Pharma; it cannot be left to Wall Street alone. - Daniel Hoyer, Chair, Department of Pharmacology, University of Melbourne, former Novartis Leading Scientist
Author Information
Founding Editor, TheScientificWorld, CEO, Corpus Alienum Oy, Finland
